---
layout: post
title:  "Reporting a statistical analysis"
categories: jekyll update
usemathjax: true
---

Here are some personal thoughts about how to report the statistical
analysis in an applied paper (e.g. medical or epidemiological study).

## Structure of the 'statistical analysis' paragraph

In the method section, the statistical paragraph should relate research questions,
generally phrased in plain English at the end of the introduction, e.g.:
> investigate the effect of psilocibin intake on the change in depressive syndroms.

to a statistical procedure producing, in fine, numerical values
reported in the result section. The precise definition of the exposure
(e.g. dosage in mg), of the outcome (e.g. clinical scale used), and
the study population (e.g. patients with MDD between 18 and 50 years),
should be defined before in the method section and are thus not
mentioned further here. A comprehensive description of the statistical
procedure would explicit:
- **the parameter of interest**, typically the mean of a random variable. Can also be a proportion, a risk (i.e. probability of an event), or a difference/ratio of mean/proportion/risk.
- **the statistical model** relating the parameter of interest to observable data.
- **the estimation procedure** used to estimate the model parameters based on the data and deduce the estimated parameter(s) of interest.
- **how uncertainty is quantified** e.g.  the procedure used to compute the standard errors and confidence intervals of the parameter(s) of interest.
- **the testing procedure** used to compute p-values. This includes null hypothesis, type of test (Wald test, score test, likelihood ratio test), and possible adjustment for multiple comparisons.

For instance:
> - To assess the difference between the psilocibin and placebo group in average 1 month change in depression score,
> - we considered a linear regression modeling the change in depression scores as a function of psilocibin intake, age, sex, ... where the regression coefficient for psilocibin intake was our parameter of interest.
> - Model parameters were estimated by Maximum Likelihood Estimation (MLE)
> - Confidence intervals where evaluated assuming Student's t-distributed estimates, with the standard error being the square root of the inverse of the expected information and the degrees of freedom equal to the number of observations minus the number of parameters for the modeling the mean.
> - a Wald test was used to test whether the difference in change was 0.

The definition of the parameter of interest is the most important
aspect, followed by the modeling procedure since it is where
assumptions are being made. In most studies, the estimation,
uncertainty, and testing procedure is more a technicality (i.e. does
not matter when interpreting the results) and can thus be omitted. There are exceptions, e.g.:
- when performing multiple tests: it is important for the interpretation to report the testing procedure, especially whether any adjustment for multiplicity was performed.
- when working with small samples: it is important to report how uncertainty is quantified, especially if the procedure does not guarantee close to nominal type 1 error control and/or coverage.

Unfortunately, statistical paragraphs are often more a list of statistical tools, e.g.:
> a logistic model was used to compare the groups in term of HAMD score

making it hard for the reader to decipher what the authors are
doing. The parameter of interest is not explicitly defined and readers
not versed in statistics will find it hard to follow. Statisticians
will also be in doubt about what the authors are actually doing, since
a statistical model can be used to target different parameters
(e.g. odds ratio or marginal difference in outcome probability between
treated and untreated).

## Example of parameter of interest 

Here are some exemple of parameters of interest that can be extracted
from classical statistical models or tests:

- **t-test, Linear models, linear mixed models, ANOVA, ANCOVA**: mean or mean
  difference

- **Chi-squared test/Fisher's Exact test**: often used to compare
  proportions (e.g. proportion of females in treatment vs. placebo
  group). It can then be preferable to switch to a
  [test](https://rdrr.io/cran/exact2x2/man/binomMeldtest.html)
  comparing directly the proportions and obtain p-values and
  confidence intervals coherent with the proportions.

- **Logistic model**: typically odds & odds ratio or, using
  [standardization](https://rdrr.io/cran/riskRegression/man/ate.html),
  risk & risk ratio/difference (risk is to be understood as the
  probability of an event). <br>
  ![](https://bozenne.github.io/img/warning.jpg){:height="30px"
  width="30px"} Odds ratios are not collapsible: [adjusting or not may
  affect the odds ratio even though the adjustment variable is not a
  confounder](https://doi.org/10.1093%2Faje%2Fkwaa267). This makes it
  hard to compare odds ratio between studies.

- **Wilcoxon-Mann-Whitney test**: [Mann-Whitney parameter, also called
  probabilistic index](https://doi.org/10.1002/sim.7890).

- **Kruskall Wallis test**: since [its test statistic can be deduced
  from the pairwise Wilcoxon
  statistics](https://doi.org/10.1093/biomet/72.3.705), one can
  consider that it has probabilistic indexes (between any two groups)
  as parameters of interest. <br>
  ![](https://bozenne.github.io/img/warning.jpg){:height="30px"
  width="30px"} [Non-parametric tests do not guarantee
  transitivity](https://doi.org/10.1016/j.jspi.2006.06.005) and can
  lead to counter-intuitive results when used to compare more than two
  groups.

- **Cox model**: hazard ratio or, using
  [standardization](https://rdrr.io/cran/riskRegression/man/ate.html),
  survival & survival ratio/difference (survival is to be understood
  as the probability of an event occuring by a specific
  timepoint). <br>
  ![](https://bozenne.github.io/img/warning.jpg){:height="30px"
  width="30px"} Using hazard ratios to make causal statements is
  generally not straightforward. Instead evaluating survival
  probabilities is [the recommended
  practice](https://doi.org/10.1097%2FEDE.0b013e3181c1ea43).

In presence of missing values or intercurrent events (e.g. death or
discontinuation of treatment) the methodology used to analyze the data
may change the underlying parameter of interest. A typical example is
ignoring the outcome values of patients after they discontinue
treatment: estimates from a mixed model adjusted on the resulting
dataset correspond to an hypothetical setting where everybody would
adhere to the treatment. Another example is instrumental variable
methods that estimate treatment effects amongst compliers ([Hernan
2006, page 363 second
column](https://doi.org/10.1097/01.ede.0000222409.00878.37)). These
examples illustrate that implications of using a specific analytical
strategy may not be obvious. The population and the setting with
respect to which the parameter of interest is defined should therefore
be described whenever they are unusual, i.e., differ from all patients
and the real world.

## Software and reproducibility

It is common to see in applied papers sentences like:
> All statistical analyses were performed using R (version 4.3.3) and the lava package (version 1.8.0)

There can be two aims with such a sentence:

- **software citation**: identify and giving credit to the authors of
  the software, which require a proper reference (instead of just
  providing a softwar version). All R packages hosted on CRAN have a
  DOI and they generally have a CITATION file indicating how they
  should be referenced in articles. These can be accessed in R by
  running ```citation() ``` and ```R.version.string``` for referencing
  the R software, and ```citation("lava")``` and
  ```packageVersion("lava")``` for referencing a specific R package
  (here lava).

- **software reproducibility**: facilitate reproducing the results or
  re-using the same methods. Again providing the software version is
  vastly insufficient. Instead one should share the code and report
  the version of the operating system, software, and all related packages
  (output of ```sessionInfo() ```). This is a lot of information and
  should be moved to online supplementary material or an online
  repository with a reference in the main paper.

So a better sentence would be:
> The R software (R Core Team, 2022) was used to implement the statistical analysis with the lava package (Holst & Budtz-Joergensen E, 2013) for estimating latent variable models. The source code, the version of R and of related software packages, can be found at https://github.com/bozenne/article-template/tree/main."

R Core Team (2024). R: A Language and Environment for Statistical
  Computing_. R Foundation for Statistical Computing, Vienna, Austria.
  <https://www.R-project.org/>. Version 4.3.3 (2024-02-29).

Klaus K. Holst and Esben Budtz-Joergensen (2013). Linear Latent
  Variable Models: The lava-package. Computational Statistics, 28 (4),
  pp. 1385-1452. doi: 10.1007/s00180-012-0344-y. Version 1.8.0.

## Common mistakes

### Introduction
- **comparing p-values between studies**, e.g. claiming results are
    conflincting between two studies because one find a significant
    p-value but not the other. P-values are not meant to be
    reproducible across studies ([Greenland
    2016](https://doi.org/10.1007/s10654-016-0149-3), 16th and 17th
    common misinterpretations of P value comparisons) as, among other
    things, they depend on the sample size (which typically greatly
    differ between studies). Comparing estimates and confidence
    intervals is often more reasonable.

### Material and methods

- **reporting p-values in a descriptive table** (typically table 1),
    or, more generally, systematic comparison of patient
    characteristics like "we compared the clinical characteristics
    between treatment groups using t-test and chi-squared test". The
    output of such analyses is often difficult to interpret (e.g. due
    to multiple testing) and not relevant (e.g. whether the mean age
    is precisely the same between the two groups is beside the
    point). Current guidelines on how to report randomized controlled
    trials ([STROBE](https://doi.org/10.1016/j.jclinepi.2010.03.004))
    and observational studies in epidemiology
    ([STROBE](https://doi.org/10.1371/journal.pmed.0040297), section
    14.a) also recommand against significance tests of baseline
    differences.

- **unadjusted per protocol analysis**. In an experimental study,
    patients may deviate from the protocol and for instance stop
    taking the treatment. It can be tempting to exclude those patients
    from the analysis. However stopping treatment is seldom random and
    often related to the outcome (e.g. full recovery, no improvement,
    or rapid deterioration) so not accounting for time-dependent
    confounders will likely lead to substantial bias. In most cases, a
    proper analysis requires specialized statistical tools ([Hern√°n,
    2017](https://doi.org/10.1056/NEJMsm1605385)).

- **claiming that all model assumptions were checked and/or are met**. This is
    simply impossible as some of the model assumptions are untestable,
    e.g. missing data at random, no unobserved confounding,
    independent and identically distributed observations.

- **confusing R Studio and the R software**. R studio is a possible
    user interface to the R software whereas the R software is where
    the actual calculations happen. I usually do not find it relevant
    to cite R studio in a scientific article.

### Results
- **concluding about the null hypothesis (i.e. no effect) based on a
  large p-value**. P-values quantify evidence against the alternative
  hypothesis (existence of an effect), not evidence in favor of the
  null hypothesis ([Greenland
  2016](https://doi.org/10.1007/s10654-016-0149-3), 5th common
  misinterpretations of single P values). Consider doing equivalence
  testing or (a priori) define what is a neglectable effect and show
  that the confidence interval only contains neglectable effects.

- **comparing p-values obtained from two different groups**,
    e.g. claiming a group difference because p<0.05 in one group but
    not the other. Instead one should compare the effect using a
    statistical test comparing the two groups or include both groups
    in a single model with an interaction and look at the interaction
    term. As mentionned in an educational note: "compare effect sizes not
    P values" ([BMJ 1996](https://doi.org/10.1136/bmj.313.7060.808)).

- **define groups based on post-baseline information**. This is
    sometimes refered to as conditioning on the future and has led to
    severely biased estimated in epidemiological studies ([Lange,
    2014](https://doi.org/10.1093/ije/dyu100), [Christensen,
    2022](https://doi.org/10.1038/s41746-021-00522-4)). Instead of
    assessing whether baseline characteristics differ between
    post-baseline groups, an analysis assessing whether the
    probability of belonging to a post-baseline group depends on
    baseline characteristics is often more easier to interpret.

- **present multiple adjusted effect estimates from a single model in
    a single table**. Consider an observational study estimating a
    treatment effect adjusted for potential confounders, say age and
    baseline severity, via a linear regression. It can be tempting to
    report all estimates from the model (treatment, age, severity) in
    the same table. This has been referred to as "the table 2 fallacy"
    ([Westreich, 2013](https://doi.org/10.1093/aje/kws412)) as the
    interpretation of the covariate effects (age and severity) can be
    far from obvious. Indeed, they may be subject to confounders other
    than the one relevant for the exposure. Moreover adjusting for the
    exposure blocks some of the confounder effect (direct instead of
    total effects). This calls for a specific model for each variable
    we would like to quantify the effect.

- **concluding about treatment effect in a single arm
    study**. Consider a study including unmedicated individuals
    (baseline) receiving a single treatment and followed over
    time. One cannot disentangle the treatment effect from time
    effects (regression to the mean, seasonal effect, natural disease
    evolution,...).


### Discusson
- **using power calculation to interpret the results**. Statistical
    power is a great tool to plan a study but not to analyze the
    results ([Hoenig, 2001](http://www.jstor.org/stable/2685525)). 

## Backtransformation

Some statistical technics involve a transformation when modeling the
exposure effect on the outcome, e.g.:
- a logistic regression uses a
  [logit](https://en.wikipedia.org/wiki/Logit) transformation.
- a log-transformation applied to the outcome before fitting a
  linear or linear mixed model. This enables to model a multiplicative
  instead of additive exposure effect: the expected increase in
  outcome when being exposed is relative to the expected unexposed
  outcome value (instead of being a specific value).

Estimated effects with their confidence intervals (but not p-values!)
should typically be back-transformed to facilitate interpretation. As
an illustration, consider a study where two groups are compared (say
active and placebo) and the log-transformed outcome is analyzed using
a linear regression. On the log-scale, we obtain an intercept of 0.5
(placebo group) and a treatment effect of 0.25. So a expected value in
the active group of 0.75.

An estimate of 0.5 would lead to back-transformed value of exp(0.5),
approximatively 1.65. The other group would get a value of 2.12. The
backtransformed treatment effect would be approximatively 1.28.

Assumming homoschedastic residuals between the two groups (on the log
scale), 1.28 is the ratio between the expected outcomes in the two
groups. Said otherwise, the mean outcome in the active group is 28%
higher compared to the placebo group. Assuming a log-normal
distribution, 1.65 and 2.12 can be interpreted as the median value in
each group and 1.28 as the ratio between the median values. <br>
![](https://bozenne.github.io/img/warning.jpg){:height="30px"
  width="30px"}: 1.65 and 2.12 are typically NOT the expected mean
  outcome value in each group. Assuming a log-normal distribution one
  would need to multiply by the exponential of half the residuals
  variance.

## Partial residuals

Providing a graphical representation associated with the results of a
statistical analysis is a common request. Displaying the raw data with
the results of a statistical test (on the same graph or in the title
or caption) can be misleading when adjusting for covariates. Indeed
the raw data would correspond to an unadjusted analysis which may
greatly differ from the adjusted analysis. The possible mismatch
between the graphical representation and the estimated summary
statistic(s) may confuse the reader.

When working with a continuous outcome, one can instead display
partial residuals. Consider the following two-arm trial:
```r
> data(ckdW, package = "LMMstar")
> ggplot(ckdW, aes(x = allocation, y = pwv0)) + geom_boxplot()
```
<br>
![](https://bozenne.github.io/img/PRES-boxplot_raw.png)
<br>

where the following statistical model was used to test the group
difference (allocation variable):
```r
> e.lmm <- lmm(pwv0 ~ allocation + sex + age, data = ckdW)
> model.tables(e.lmm)
```
                  estimate         se      df      lower    upper      p.value
    (Intercept) -0.6701892 1.98683016 47.0094 -4.6671548 3.326776 7.373804e-01
    allocationB  0.3269616 0.82004599 47.0094 -1.3227494 1.976673 6.919113e-01
    sexmale      0.8474481 0.95876696 47.0094 -1.0813321 2.776228 3.812519e-01
    age          0.1682865 0.03246632 47.0094  0.1029731 0.233600 4.510612e-06


We obtain a mean group difference of 0.327 [-1.323;1.977] instead of
0.266 [-1.806;2.339] had we not have adjusted for sex and age. The
previous figure where we display the (raw) outcome per group is
therefore not appropriate to illustrate the estimated drug
effect. Instead one could provide a graphical representation of the
partial residuals:
```r
> plot(e.lmm, type = "partial", variable = "allocation")
```

<br>
![](https://bozenne.github.io/img/PRES-boxplot_partial0.png)
<br>

Indead the difference in mean partial residuals between the two groups:
```r
> ckdW$pres <- residuals(e.lmm, type = "partial", variable = "allocation")
> mean(ckdW$pres[ckdW$allocation=="B"]) - mean(ckdW$pres[ckdW$allocation=="A"])
```
    [1] 0.3269616

is exactly the estimated drug effect. One counter-intuitive feature of
partial residuals is that there may not follow the original scale
(they are typically centered around 0 wherease the outcome value was
strictly positive):
```r
> head(ckdW$pres)
```
    [1] -2.7098727 -2.3524574 -1.6281556 -0.1672843 -0.5647286 -2.4024574

Assuming that the model holds, the display is to be understood as the
outcome we would have observed had all individuals have had the same
sex (here female) and same age (here age 0). Another counter-intuitive
feature is that continuous variables have by default reference level 0
which in the case of age is un-realistic. The first issue can be fixed
by keeping the intercept (argument var) and the second by specifying
the reference levels:
```r
> plot(e.lmm, type = "partial", variable = c("(Intercept)","allocation"), 
       at = data.frame(sex = factor("female", levels(ckdW$sex)), age = 58))
```
<br>
![](https://bozenne.github.io/img/PRES-boxplot_partial.png)
<br>

```r
> ckdW$pres.f28 <- residuals(e.lmm, type = "partial", variable = c("(Intercept)","allocation"), 
                             at = data.frame(sex = factor("female", levels(ckdW$sex)), age = 58))
> head(ckdW$pres.f28)
```
    [1] 6.380558 6.737973 7.462275 8.923146 8.525702 6.687973

This simplify shift the partial residuals by value, here:
```r
> unique(round(ckdW$pres.f28-ckdW$pres,10))
```
    [1] 9.09043

See the
[vignette](https://cran.r-project.org/web/packages/LMMstar/vignettes/partial-residuals.pdf)
of the LMMstar package for more examples


## Greek letters and notations

There is no intrinsic meanning to \(\beta\), \(\rho\), ... One should
define what each refers to in the statistical analysis
paragraph. Avoid to use the same letter to refer to two different
things. It can be a good idea to use \(p\) to refer to p-values
relative to a single test and \(p_{adj}\) to FWER adjusted
p-values. In the latter case, it should be made clear over which/how
many tests the FWER is evaluated.
